<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339507</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-05-11</org_study_id>
    <nct_id>NCT01339507</nct_id>
  </id_info>
  <brief_title>A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft</brief_title>
  <official_title>A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft in Patients With a History of Allergic Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cunningham, Derek N., O.D., P.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cunningham, Derek N., O.D., P.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the comfort of BEPREVE compared to LASTACAFT after
      instillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After one drop is instilled subjects will complete a comfort assessment at 1, 3, 5, and 10
      minutes after drop instillation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Bepreve</arm_group_label>
    <description>Subjects with a history of allergic conjunctivitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lastacaft</arm_group_label>
    <description>Subjects with a history of allergic conjunctivitis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are diagnosed with allergic conjunctivitis and who meet all other
        inclusion/exclusion criteria will be eligible to enter the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each patient must meet the following criteria to be enrolled in this study:

          1. Are male or female at least 18 years of age who are diagnosed with allergic
             conjunctivitis.

          2. Have allergic ocular symptoms within the last three days.

          3. Are willing/able to follow instructions from the study investigator and his/her staff.

          4. Have signed informed consent approved by Institutional Review Board or Independent
             Ethics Committee.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from the study:

          1. Have known hypersensitivity to either BEPREVE™ or LASTACAFT® or to any component of
             the test article (including &quot;procedural&quot; medications such as anesthetic and/or
             fluorescein drops, dilating drops, etc.).

          2. Have active corneal pathology noted in the study eye at the screening visit. Active
             corneal pathology is defined as corneal pathology that is non stable, or greater than
             mild, or will compromise assessment of the safety or efficacy of treatment.

          3. Are pregnant or nursing/lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Cunningham, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dell Laser Consultants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Derek Cunningham</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2011</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cunningham, Derek N., O.D., P.A.</investigator_affiliation>
    <investigator_full_name>Derek N. Cunningham</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcaftadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

